Puma Biotechnology, Inc. (PBYI) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PBYI Revenue Growth
Revenue Breakdown (FY 2025)
PBYI's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PBYI Revenue Analysis (2014–2025)
As of May 8, 2026, Puma Biotechnology, Inc. (PBYI) generated trailing twelve-month (TTM) revenue of $227.2 million, reflecting slight decline in growth of -2.6% year-over-year. The most recent quarter (Q1 2026) recorded $44.8 million in revenue, down 40.7% sequentially.
Looking at the longer-term picture, PBYI's 5-year compound annual growth rate (CAGR) stands at +0.3%, indicating moderate growth over time. The company achieved its highest annual revenue of $272.3 million in 2019.
Revenue diversification analysis shows PBYI's business is primarily driven by Product (89%), and Royalty (11%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), TGTX (+81.3% YoY), and PTCT (-53.3% YoY), PBYI has underperformed the peer group in terms of revenue growth. Compare PBYI vs RCUS →
PBYI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PBYICurrent | $227M | -2.6% | +0.3% | 16.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% |
PBYI Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $228.4M | -0.9% | $170.2M | 74.5% | $37.3M | 16.3% |
| 2024 | $230.5M | -2.2% | $166.1M | 72.1% | $31.0M | 13.4% |
| 2023 | $235.6M | +3.3% | $173.0M | 73.4% | $32.6M | 13.9% |
| 2022 | $228.0M | -9.9% | $172.9M | 75.8% | $23.7M | 10.4% |
| 2021 | $253.2M | +12.5% | $189.5M | 74.8% | $1.3M | 0.5% |
| 2020 | $225.1M | -17.3% | $185.7M | 82.5% | $-30,402,000 | -13.5% |
| 2019 | $272.3M | +8.5% | $235.4M | 86.5% | $-75,595,000 | -27.8% |
| 2018 | $251.0M | +806.1% | $216.4M | 86.2% | $-94,700,000 | -37.7% |
| 2017 | $27.7M | - | $22.1M | 79.8% | $-292,400,000 | -1055.6% |
| 2016 | $0 | - | $-1,149,000 | - | $-276,600,000 | - |
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PBYI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
Is PBYI's revenue growth accelerating or slowing?
PBYI revenue growth slowed to -2.6%, below the 5-year CAGR of +0.3%. TTM revenue is $227M. The deceleration marks a shift from historical growth rates.
What is PBYI's long-term revenue growth rate?
Puma Biotechnology, Inc.'s 5-year revenue CAGR of +0.3% reflects the variable expansion pattern. Current YoY growth of -2.6% is near this long-term average.
How is PBYI's revenue distributed by segment?
PBYI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.